Ruxolitinib Combo Elicits Responses in Small GVHD Population
February 23rd 2024Large studies may be warranted to evaluate the efficacy, safety, and durability of response in patients who receive ruxolitinib plus belumosudil for graft-versus-host disease, according to the authors of a retrospective analysis.